Research hotspots of prostate cancer at the international conferences on urology in 2022.
10.3724/zdxbyxb-2022-0712
- Author:
Jiahe YI
1
;
Jiangfeng LI
2
;
Liping XIE
3
Author Information
1. Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. 12218350@zju.edu.cn.
2. Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
3. Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. xielp@zju.edu.cn.
- Publication Type:Journal Article
- Keywords:
PSMA-PET/CT;
Prostate biopsy;
Prostate cancer;
Prostate-specific antigen;
Reviews
- MeSH:
Male;
Humans;
Urology;
Positron Emission Tomography Computed Tomography/methods*;
Prostatic Neoplasms/pathology*;
Multiparametric Magnetic Resonance Imaging/methods*;
Gallium Radioisotopes
- From:
Journal of Zhejiang University. Medical sciences
2023;52(2):178-184
- CountryChina
- Language:English
-
Abstract:
The American Urological Association (AUA), European Association of Urology (EUA) and International Urological Society (SIU) annual meetings were held in 2022. Studies on prostate cancer reported in the meetings mainly focus on the advances of diagnostic biomarkers (such as α-2, 3-1inked sialylation of terminal N-glycan on free PSA density, SelectMDx) and imaging techniques [such as multiparametric magnetic resonance imaging, prostate specific membrane antigen(PSMA)-PET/CT], the new method for prostate biopsy, the new treatments of prostate cancer including [177Lu] Ludotadipep and DROP-IN PSMA probe, and the prognosis assessment of prostate cancer (such as AR-V7). This article provides an overview on the research hotspots of three international academic meetings.
